Literature DB >> 8341396

Use of tissue plasminogen activator for reopening of clotted dialysis catheters.

D Paulsen1, A Reisoether, M Aasen, P Fauchald.   

Abstract

The use of central venous catheters as permanent vascular access in chronic hemodialysis is complicated by clotting. We have tried a nonallergenic thrombolytic agent, tissue plasminogen activator (t-PA), to dissolve catheter luminal thrombosis. Eight patients, 7 in chronic hemodialysis and 1 treated by immune adsorption had 18 treatments with locally applied t-PA (2 mg/2 cm3). Fifteen out of 16 treatments with longer bolus dwell than 60 min were successful. No side effects occurred. t-PA dissolves clot formation efficiently and safely, the drug is nonallergenic and can therefore be given repeatedly.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8341396     DOI: 10.1159/000187374

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  3 in total

1.  Improvement of hemodialysis catheter function with tenecteplase: a phase III, open-label study: TROPICS 4.

Authors:  Steven Fishbane; Samuel L Milligan; Kenneth D Lempert; Joachim E W Hertel; James B Wetmore; Matthew J Oliver; Martha Blaney; Barbara S Gillespie; Joan R Jacobs; Susan M Begelman
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

2.  Thrombolysis for restoration of patency to haemodialysis central venous catheters: a systematic review.

Authors:  C M Clase; M A Crowther; A J Ingram; C S Cinà
Journal:  J Thromb Thrombolysis       Date:  2001-04       Impact factor: 2.300

3.  A phase III, randomized, double-blind, placebo-controlled study of tenecteplase for improvement of hemodialysis catheter function: TROPICS 3.

Authors:  James Tumlin; Jesse Goldman; David M Spiegel; David Roer; K Adu Ntoso; Martha Blaney; Joan Jacobs; Barbara S Gillespie; Susan M Begelman
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-04       Impact factor: 8.237

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.